Investors Aligned Against Cardlytics in Class Action Lawsuit
In a significant development for investors holding shares of Cardlytics, Inc. (NASDAQ: CDLX), Bronstein, Gewirtz & Grossman, LLC, a noted law firm, has announced a class action lawsuit against the company and its executives. This legal action provides a chance for those who've experienced substantial losses to seek potential compensation.
Understanding the Class Definition
This lawsuit is aimed at recovering damages for alleged violations of federal securities laws. Specifically, it targets all individuals and entities that purchased Cardlytics securities during the class period, which spans from March 14, 2024, until August 7, 2024. If you’ve held Cardlytics shares in this timeframe, you might be able to participate in this legal case.
Details of the Case Against Cardlytics
The complaint outlines serious allegations against the defendants. Throughout the specified class period, they reportedly made materially false and misleading statements. There was also a failure to disclose critical adverse facts concerning the company’s operations and future prospects. Major claims include unduly optimistic projections about consumer engagement, which led to increased incentives. This resulted in a failure to align revenue growth with actual engagement levels, raising concerns about potential declines in revenue. Furthermore, these revelations could suggest that the positive statements made by the defendants lacked substantial grounding.
What Steps Should Investors Take?
With a class action lawsuit already underway, affected investors are encouraged to act promptly. If you wish to review the full details of the complaint, visiting the law firm’s website can be beneficial. In addition, investors may contact Peretz Bronstein or Client Relations Manager Nathan Miller at 332-239-2660 for more information. Remember, you have until March 25, 2025, to ask the court to appoint you as the lead plaintiff if you experienced losses with Cardlytics stock. Participation in a recovery does not necessitate leading the lawsuit.
Financial Representation Without Cost
The law firm operates on a contingency fee basis when handling class action lawsuits. This means that if they successfully secure damages for investors, they will only recover their out-of-pocket expenses and attorneys’ fees as a percentage of the total recovery amount.
About Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman is recognized nationally for its vigorous representation of investors in cases of securities fraud and shareholder derivative lawsuits. Having recovered hundreds of millions for investors across the country, they have established a strong reputation in the legal community, making them a reliable ally for affected investors.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Cardlytics?
The lawsuit aims to recover damages for investors who suffered losses due to alleged misleading statements and failures in disclosure by Cardlytics and its executives.
Who qualifies to be part of the class action?
Anyone who purchased Cardlytics securities between March 14, 2024, and August 7, 2024, may qualify to join the class action.
What can investors expect from participating in the lawsuit?
Investors may have the opportunity to recoup some of their losses if the lawsuit results in a successful outcome for the class. This does not necessitate being a lead plaintiff.
Is there a cost involved in joining the lawsuit?
No, there is no cost to participate upfront. The law firm operates on a contingency basis, meaning they only get paid if they win the case.
How can investors get more information about the lawsuit?
Investors can visit the law firm’s website or contact the representatives directly at Bronstein, Gewirtz & Grossman for detailed information and updates regarding the case.
